The spatiotemporal pattern of Ezrin/Periaxin expression was involved in the control of myoblast differentiation/fusion, myotube length and size, and myofiber specialization, which was related to the activated PKA-NFAT-MEF2C signaling pathway, providing a novel L-Periaxin/Ezrin joint strategy for the treatment of muscle atrophy, especially in CMT4F (Fig. 9). The gene discussed is MEF2C; the disease is Charcot-Marie-Tooth disease type 4F.